Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity.

Ramírez-Moya J, Baker AR, Slack FJ, Santisteban P.

Oncogene. 2020 Mar 10. doi: 10.1038/s41388-020-1248-x. [Epub ahead of print]

PMID:
32157211
2.

A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells.

Rupaimoole R, Yoon B, Zhang WC, Adams BD, Slack FJ.

iScience. 2020 Feb 21;23(2):100878. doi: 10.1016/j.isci.2020.100878. Epub 2020 Feb 1.

3.

Hydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo.

Segal M, Biscans A, Gilles ME, Anastasiadou E, De Luca R, Lim J, Khvorova A, Slack FJ.

Mol Ther Nucleic Acids. 2020 Mar 6;19:267-277. doi: 10.1016/j.omtn.2019.11.008. Epub 2019 Nov 18.

4.

The Role of Non-coding RNAs in Oncology.

Slack FJ, Chinnaiyan AM.

Cell. 2019 Nov 14;179(5):1033-1055. doi: 10.1016/j.cell.2019.10.017. Review.

PMID:
31730848
5.

miR-155 as a novel clinical target for hematological malignancies.

Witten L, Slack FJ.

Carcinogenesis. 2020 Mar 13;41(1):2-7. doi: 10.1093/carcin/bgz183.

PMID:
31711135
6.

Sex-Dependent Changes in miRNA Expression in the Bed Nucleus of the Stria Terminalis Following Stress.

Mavrikaki M, Pantano L, Potter D, Rogers-Grazado MA, Anastasiadou E, Slack FJ, Amr SS, Ressler KJ, Daskalakis NP, Chartoff E.

Front Mol Neurosci. 2019 Oct 4;12:236. doi: 10.3389/fnmol.2019.00236. eCollection 2019.

7.

miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma.

Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, Melnick MA, Politi K, Asara JM, Costa DB, Bult CJ, Slack FJ.

Nat Metab. 2019 Apr;1(4):460-474. doi: 10.1038/s42255-019-0052-9. Epub 2019 Apr 8.

8.

Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer.

Gilles ME, Hao L, Brown K, Lim J, Bhatia SN, Slack FJ.

Oncotarget. 2019 Sep 3;10(51):5349-5358. doi: 10.18632/oncotarget.27160. eCollection 2019 Sep 3.

9.

Extracellular vesicles show promise for cancer theranostics.

Segal M, Slack FJ.

Ann Transl Med. 2019 Apr;7(7):158. doi: 10.21037/atm.2019.03.19. No abstract available.

10.

Overexpression of miR-9 in the Nucleus Accumbens Increases Oxycodone Self-Administration.

Mavrikaki M, Anastasiadou E, Ozdemir RA, Potter D, Helmholz C, Slack FJ, Chartoff EH.

Int J Neuropsychopharmacol. 2019 Jun 3;22(6):383-393. doi: 10.1093/ijnp/pyz015.

11.

Epstein-Barr virus: From kisses to cancer, an ingenious immune evader.

Trivedi P, Slack FJ, Anastasiadou E.

Oncotarget. 2018 Nov 23;9(92):36411-36412. doi: 10.18632/oncotarget.26381. eCollection 2018 Nov 23. No abstract available.

12.

Human nuclear RNAi-defective 2 (NRDE2) is an essential RNA splicing factor.

Jiao AL, Perales R, Umbreit NT, Haswell JR, Piper ME, Adams BD, Pellman D, Kennedy S, Slack FJ.

RNA. 2019 Mar;25(3):352-363. doi: 10.1261/rna.069773.118. Epub 2018 Dec 11.

13.

miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene.

Witten LW, Cheng CJ, Slack FJ.

Oncogene. 2019 Mar;38(12):2151-2161. doi: 10.1038/s41388-018-0571-y. Epub 2018 Nov 20.

PMID:
30459357
14.

Let-7 microRNA as a potential therapeutic target with implications for immunotherapy.

Gilles ME, Slack FJ.

Expert Opin Ther Targets. 2018 Nov;22(11):929-939. doi: 10.1080/14728222.2018.1535594. Epub 2018 Oct 17. Review.

15.

mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis.

Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, Santisteban P, George RE, Richards WG, Wong KK, Locker N, Slack FJ, Gregory RI.

Nature. 2018 Sep;561(7724):556-560. doi: 10.1038/s41586-018-0538-8. Epub 2018 Sep 19.

16.

Nonfouling, Encoded Hydrogel Microparticles for Multiplex MicroRNA Profiling Directly from Formalin-Fixed, Paraffin-Embedded Tissue.

Nagarajan MB, Tentori AM, Zhang WC, Slack FJ, Doyle PS.

Anal Chem. 2018 Sep 4;90(17):10279-10285. doi: 10.1021/acs.analchem.8b02010. Epub 2018 Aug 14.

17.

Compulsive Buying: The Impact of Attitudes Toward Body Image, Eating Disorders, and Physical Appearance Investment.

Harnish RJ, Gump JT, Bridges KR, Slack FJ, Rottschaefer KM.

Psychol Rep. 2019 Oct;122(5):1632-1650. doi: 10.1177/0033294118789042. Epub 2018 Jul 25.

PMID:
30043676
18.

The Nefarious Nexus of Noncoding RNAs in Cancer.

Anastasiadou E, Faggioni A, Trivedi P, Slack FJ.

Int J Mol Sci. 2018 Jul 17;19(7). pii: E2072. doi: 10.3390/ijms19072072. Review.

19.

Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays.

Tentori AM, Nagarajan MB, Kim JJ, Zhang WC, Slack FJ, Doyle PS.

Lab Chip. 2018 Aug 7;18(16):2410-2424. doi: 10.1039/c8lc00498f.

20.

Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.

Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ.

Leukemia. 2019 Jan;33(1):132-147. doi: 10.1038/s41375-018-0178-x. Epub 2018 Jun 26.

21.

Tackling Tumors with Small RNAs Derived from Transfer RNA.

Slack FJ.

N Engl J Med. 2018 May 10;378(19):1842-1843. doi: 10.1056/NEJMcibr1716989. No abstract available.

PMID:
29742367
22.

Personalized RNA Medicine for Pancreatic Cancer.

Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, Jeong JC, Muthuswamy SK, Hidalgo M, Bhatia SN, Slack FJ.

Clin Cancer Res. 2018 Apr 1;24(7):1734-1747. doi: 10.1158/1078-0432.CCR-17-2733. Epub 2018 Jan 12.

23.

lin-4 and the NRDE pathway are required to activate a transgenic lin-4 reporter but not the endogenous lin-4 locus in C. elegans.

Jiao AL, Foster DJ, Dixon J, Slack FJ.

PLoS One. 2018 Jan 11;13(1):e0190766. doi: 10.1371/journal.pone.0190766. eCollection 2018.

24.

Non-coding RNA networks in cancer.

Anastasiadou E, Jacob LS, Slack FJ.

Nat Rev Cancer. 2018 Jan;18(1):5-18. doi: 10.1038/nrc.2017.99. Epub 2017 Nov 24. Review.

25.

A microRNA feedback loop regulates global microRNA abundance during aging.

Inukai S, Pincus Z, de Lencastre A, Slack FJ.

RNA. 2018 Feb;24(2):159-172. doi: 10.1261/rna.062190.117. Epub 2017 Nov 7.

26.

acn-1, a C. elegans homologue of ACE, genetically interacts with the let-7 microRNA and other heterochronic genes.

Metheetrairut C, Ahuja Y, Slack FJ.

Cell Cycle. 2017 Oct 2;16(19):1800-1809. doi: 10.1080/15384101.2017.1344798. Epub 2017 Sep 21.

27.

Targeting noncoding RNAs in disease.

Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ.

J Clin Invest. 2017 Mar 1;127(3):761-771. doi: 10.1172/JCI84424. Epub 2017 Mar 1. Review.

28.

MicroRNA therapeutics: towards a new era for the management of cancer and other diseases.

Rupaimoole R, Slack FJ.

Nat Rev Drug Discov. 2017 Mar;16(3):203-222. doi: 10.1038/nrd.2016.246. Epub 2017 Feb 17. Review.

PMID:
28209991
29.

A serum miRNA profile of human longevity: findings from the Baltimore Longitudinal Study of Aging (BLSA).

Smith-Vikos T, Liu Z, Parsons C, Gorospe M, Ferrucci L, Gill TM, Slack FJ.

Aging (Albany NY). 2016 Nov 7;8(11):2971-2987. doi: 10.18632/aging.101106.

30.

A role for miR-34 in colon cancer stem cell homeostasis.

Rupaimoole R, Slack FJ.

Stem Cell Investig. 2016 Aug 24;3:42. doi: 10.21037/sci.2016.08.04. eCollection 2016. No abstract available.

31.

ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity.

Zhang WC, Slack FJ.

Cell Stem Cell. 2016 Aug 4;19(2):141-142. doi: 10.1016/j.stem.2016.07.012.

32.

OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer.

Svoronos AA, Engelman DM, Slack FJ.

Cancer Res. 2016 Jul 1;76(13):3666-70. doi: 10.1158/0008-5472.CAN-16-0359. Epub 2016 Jun 20. Review.

33.

cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation.

Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ.

Oncogene. 2017 Jan 26;36(4):512-524. doi: 10.1038/onc.2016.222. Epub 2016 Jun 20.

34.

Autofluorescence as a measure of senescence in C. elegans: look to red, not blue or green.

Pincus Z, Mazer TC, Slack FJ.

Aging (Albany NY). 2016 May;8(5):889-98. doi: 10.18632/aging.100936.

35.

miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage.

Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB.

Nat Commun. 2016 Mar 21;7:10954. doi: 10.1038/ncomms10954.

36.

Cis-acting elements in its 3' UTR mediate post-transcriptional regulation of KRAS.

Kim M, Kogan N, Slack FJ.

Oncotarget. 2016 Mar 15;7(11):11770-84. doi: 10.18632/oncotarget.7599.

37.

miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.

Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ.

Cancer Res. 2016 Feb 15;76(4):927-39. doi: 10.1158/0008-5472.CAN-15-2321. Epub 2015 Dec 16.

38.

The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas.

Adams BD, Parsons C, Slack FJ.

Expert Opin Ther Targets. 2016 Jun;20(6):737-53. doi: 10.1517/14728222.2016.1114102. Epub 2015 Dec 11. Review.

39.

The Inescapable Influence of Noncoding RNAs in Cancer.

Adams BD, Anastasiadou E, Esteller M, He L, Slack FJ.

Cancer Res. 2015 Dec 15;75(24):5206-10.

40.

Estrogen withdrawal, increased breast cancer risk and the KRAS-variant.

McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB.

Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11.

41.

A novel mechanism of LIN-28 regulation of let-7 microRNA expression revealed by in vivo HITS-CLIP in C. elegans.

Stefani G, Chen X, Zhao H, Slack FJ.

RNA. 2015 May;21(5):985-96. doi: 10.1261/rna.045542.114. Epub 2015 Mar 24.

42.

Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation.

Stahlhut C, Slack FJ.

Cell Cycle. 2015;14(13):2171-80. doi: 10.1080/15384101.2014.1003008. Epub 2015 Feb 25.

43.

Junk DNA and the long non-coding RNA twist in cancer genetics.

Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ, Calin GA.

Oncogene. 2015 Sep 24;34(39):5003-11. doi: 10.1038/onc.2014.456. Epub 2015 Jan 26. Review.

44.

Cancer. Malicious exosomes.

Anastasiadou E, Slack FJ.

Science. 2014 Dec 19;346(6216):1459-60. doi: 10.1126/science.aaa4024. No abstract available.

PMID:
25525233
45.

MicroRNA-mediated regulation of KRAS in cancer.

Kim M, Slack FJ.

J Hematol Oncol. 2014 Nov 30;7:84. doi: 10.1186/s13045-014-0084-2. Review.

46.

MicroRNA silencing for cancer therapy targeted to the tumour microenvironment.

Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ.

Nature. 2015 Feb 5;518(7537):107-10. doi: 10.1038/nature13905. Epub 2014 Nov 17.

47.

Expression inactivation of SMARCA4 by microRNAs in lung tumors.

Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C, Boyero-Corral L, Carretero J, Farez-Vidal E, Cuadros M, Reyes-Zurita FJ, Lupiáñez JA, Sánchez-Cespedes M, Slack FJ, Medina PP.

Hum Mol Genet. 2015 Mar 1;24(5):1400-9. doi: 10.1093/hmg/ddu554. Epub 2014 Oct 29.

48.

MicroRNAs mediate dietary-restriction-induced longevity through PHA-4/FOXA and SKN-1/Nrf transcription factors.

Smith-Vikos T, de Lencastre A, Inukai S, Shlomchik M, Holtrup B, Slack FJ.

Curr Biol. 2014 Oct 6;24(19):2238-46. doi: 10.1016/j.cub.2014.08.013. Epub 2014 Sep 18.

49.

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.

Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ.

Oncogene. 2015 Jul;34(27):3547-55. doi: 10.1038/onc.2014.282. Epub 2014 Sep 1.

50.

Comparative analysis of the transcriptome across distant species.

Gerstein MB, Rozowsky J, Yan KK, Wang D, Cheng C, Brown JB, Davis CA, Hillier L, Sisu C, Li JJ, Pei B, Harmanci AO, Duff MO, Djebali S, Alexander RP, Alver BH, Auerbach R, Bell K, Bickel PJ, Boeck ME, Boley NP, Booth BW, Cherbas L, Cherbas P, Di C, Dobin A, Drenkow J, Ewing B, Fang G, Fastuca M, Feingold EA, Frankish A, Gao G, Good PJ, Guigó R, Hammonds A, Harrow J, Hoskins RA, Howald C, Hu L, Huang H, Hubbard TJ, Huynh C, Jha S, Kasper D, Kato M, Kaufman TC, Kitchen RR, Ladewig E, Lagarde J, Lai E, Leng J, Lu Z, MacCoss M, May G, McWhirter R, Merrihew G, Miller DM, Mortazavi A, Murad R, Oliver B, Olson S, Park PJ, Pazin MJ, Perrimon N, Pervouchine D, Reinke V, Reymond A, Robinson G, Samsonova A, Saunders GI, Schlesinger F, Sethi A, Slack FJ, Spencer WC, Stoiber MH, Strasbourger P, Tanzer A, Thompson OA, Wan KH, Wang G, Wang H, Watkins KL, Wen J, Wen K, Xue C, Yang L, Yip K, Zaleski C, Zhang Y, Zheng H, Brenner SE, Graveley BR, Celniker SE, Gingeras TR, Waterston R.

Nature. 2014 Aug 28;512(7515):445-8. doi: 10.1038/nature13424.

Supplemental Content

Loading ...
Support Center